MX2017013880A - Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. - Google Patents
Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.Info
- Publication number
- MX2017013880A MX2017013880A MX2017013880A MX2017013880A MX2017013880A MX 2017013880 A MX2017013880 A MX 2017013880A MX 2017013880 A MX2017013880 A MX 2017013880A MX 2017013880 A MX2017013880 A MX 2017013880A MX 2017013880 A MX2017013880 A MX 2017013880A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydronaphthyridinyl
- propionic acid
- acid derivatives
- fibrosis
- treating
- Prior art date
Links
- ZPQLOGVWIFHBAY-UHFFFAOYSA-N 2-(3,4-dihydro-2H-1,8-naphthyridin-1-yl)propanoic acid Chemical class N1(CCCC2=CC=CN=C12)C(C(=O)O)C ZPQLOGVWIFHBAY-UHFFFAOYSA-N 0.000 title 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562154894P | 2015-04-30 | 2015-04-30 | |
| PCT/US2016/029962 WO2016176532A1 (en) | 2015-04-30 | 2016-04-29 | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013880A true MX2017013880A (es) | 2018-08-01 |
Family
ID=56027176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013880A MX2017013880A (es) | 2015-04-30 | 2016-04-29 | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9572801B2 (enExample) |
| EP (1) | EP3288555A1 (enExample) |
| JP (1) | JP2018514568A (enExample) |
| KR (1) | KR20170141757A (enExample) |
| CN (1) | CN108040467A (enExample) |
| AU (1) | AU2016255494A1 (enExample) |
| BR (1) | BR112017023432A2 (enExample) |
| CA (1) | CA2983312A1 (enExample) |
| IL (1) | IL255054A0 (enExample) |
| MX (1) | MX2017013880A (enExample) |
| RU (1) | RU2017141561A (enExample) |
| WO (1) | WO2016176532A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2953948T (lt) | 2013-02-07 | 2018-01-10 | Scifluor Life Sciences, Inc | Fluorinti integrino antagonistai |
| US8901144B2 (en) * | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| RU2017132433A (ru) | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
| US10118929B2 (en) | 2016-04-27 | 2018-11-06 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
| AU2018229275B2 (en) | 2017-02-28 | 2021-12-23 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| MA52117A (fr) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| CA3097656A1 (en) | 2018-04-27 | 2019-10-31 | Arrowhead Pharmaceuticals, Inc. | Integrin targeting ligands and uses thereof |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020081154A1 (en) | 2018-08-29 | 2020-04-23 | Morphic Therapeutic, Inc. | INHIBITORS OF ανβ6 INTEGRIN |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| KR20230049584A (ko) * | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
| JP7585564B2 (ja) * | 2020-09-24 | 2024-11-19 | 株式会社ファンケル | セラミド含有ニオソームを含む化粧料 |
| CN119255801A (zh) * | 2022-05-30 | 2025-01-03 | 赛诺哈勃药业（成都）有限公司 | 四氢萘啶衍生物在制备防治粘连相关疾病的药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1318254C (en) | 1988-01-06 | 1993-05-25 | Munehiro Tomikawa | Inhibitory agent of hepatic fibrosis containing pantethine |
| ATE153500T1 (de) | 1991-04-01 | 1997-06-15 | Univ Duke | Verfahren zur inhibierung der fibrose |
| JP3818322B2 (ja) | 1994-04-28 | 2006-09-06 | 敏一 中村 | コラーゲン分解促進剤 |
| US5645839A (en) | 1995-06-07 | 1997-07-08 | Trustees Of Boston University | Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis |
| US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| WO1998008528A1 (en) | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| CN1284955A (zh) * | 1997-12-17 | 2001-02-21 | 麦克公司 | 整联蛋白受体拮抗剂 |
| US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
| US6117445A (en) | 1998-01-28 | 2000-09-12 | Link Technology Inc. | Methods for the prevention and treatment of fibrosis and sclerosis |
| WO2001062292A1 (en) | 2000-02-22 | 2001-08-30 | Suntory Limited | Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient |
| EP1319002A1 (en) * | 2000-09-14 | 2003-06-18 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| US6509347B2 (en) * | 2001-06-11 | 2003-01-21 | Merck & Co., Inc. | Crystalline forms of an integrin receptor antagonist |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| LT2953948T (lt) | 2013-02-07 | 2018-01-10 | Scifluor Life Sciences, Inc | Fluorinti integrino antagonistai |
| RU2017132433A (ru) * | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
| EP3273965A4 (en) * | 2015-03-26 | 2018-12-05 | Merck Sharp & Dohme Corp. | Composition and methods for treating chronic kidney disease |
-
2016
- 2016-04-29 JP JP2017556988A patent/JP2018514568A/ja not_active Withdrawn
- 2016-04-29 AU AU2016255494A patent/AU2016255494A1/en not_active Abandoned
- 2016-04-29 US US15/142,023 patent/US9572801B2/en not_active Expired - Fee Related
- 2016-04-29 EP EP16724172.8A patent/EP3288555A1/en not_active Withdrawn
- 2016-04-29 MX MX2017013880A patent/MX2017013880A/es unknown
- 2016-04-29 WO PCT/US2016/029962 patent/WO2016176532A1/en not_active Ceased
- 2016-04-29 KR KR1020177034091A patent/KR20170141757A/ko not_active Withdrawn
- 2016-04-29 CA CA2983312A patent/CA2983312A1/en not_active Abandoned
- 2016-04-29 RU RU2017141561A patent/RU2017141561A/ru not_active Application Discontinuation
- 2016-04-29 BR BR112017023432A patent/BR112017023432A2/pt not_active Application Discontinuation
- 2016-04-29 CN CN201680036759.2A patent/CN108040467A/zh active Pending
-
2017
- 2017-10-16 IL IL255054A patent/IL255054A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN108040467A (zh) | 2018-05-15 |
| KR20170141757A (ko) | 2017-12-26 |
| RU2017141561A (ru) | 2019-05-31 |
| WO2016176532A1 (en) | 2016-11-03 |
| BR112017023432A2 (pt) | 2018-07-24 |
| IL255054A0 (en) | 2017-12-31 |
| US20160317527A1 (en) | 2016-11-03 |
| EP3288555A1 (en) | 2018-03-07 |
| US9572801B2 (en) | 2017-02-21 |
| JP2018514568A (ja) | 2018-06-07 |
| AU2016255494A1 (en) | 2017-11-02 |
| CA2983312A1 (en) | 2016-11-03 |
| RU2017141561A3 (enExample) | 2019-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013880A (es) | Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos. | |
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12017501016B1 (en) | Triazolopyrimidine compounds and uses thereof | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| PH12016501388A1 (en) | Heteroaryls and uses thereof | |
| AU2015207757A8 (en) | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| SG10201809518QA (en) | Processes of preparing a jak1 inhibitor and new forms thereto | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| JO3317B1 (ar) | مركبات تترا هيدروبيرولو ثيازين | |
| MY188447A (en) | Indazole compounds as fger kinase inhibitor, preparation and use thereof | |
| GEP20186887B (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| MA40171A (fr) | Dérivés d'azamophinan et leur utilisation | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
| MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
| AU2016204294A1 (en) | Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| MX2018005004A (es) | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| MY199524A (en) | Anti-angiogenic agents and uses thereof |